Drug Profile
BMS 986183
Alternative Names: BMS-986183; BMS-986183-01Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Liver cancer in USA (unspecified route) (Bristol-Myers Squibb pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Liver-cancer in USA
- 09 Nov 2018 Discontinued - Phase-I/II for Liver cancer (Late-stage disease) in Taiwan, South Korea, Singapore, Canada (unspecified route) (NCT02828124)